首页> 美国卫生研究院文献>Journal of Biomedical Optics >Review of clinical approaches in fluorescence lifetime imaging ophthalmoscopy
【2h】

Review of clinical approaches in fluorescence lifetime imaging ophthalmoscopy

机译:荧光寿命成像眼压术临床方法综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Autofluorescence-based imaging techniques have become very important in the ophthalmological field. Being noninvasive and very sensitive, they are broadly used in clinical routines. Conventional autofluorescence intensity imaging is largely influenced by the strong fluorescence of lipofuscin, a fluorophore that can be found at the level of the retinal pigment epithelium. However, different endogenous retinal fluorophores can be altered in various diseases. Fluorescence lifetime imaging ophthalmoscopy (FLIO) is an imaging modality to investigate the autofluorescence of the human fundus in vivo. It expands the level of information, as an addition to investigating the fluorescence intensity, and autofluorescence lifetimes are captured. The Heidelberg Engineering Spectralis-based fluorescence lifetime imaging ophthalmoscope is used to investigate a 30-deg retinal field centered at the fovea. It detects FAF decays in short [498 to 560 nm, short spectral channel (SSC) and long (560 to 720 nm, long spectral channel (LSC)] spectral channels, the mean fluorescence lifetimes (τm) are calculated using bi- or triexponential approaches. These are meant to be relatively independent of the fluorophore’s intensity; therefore, fluorophores with less intense fluorescence can be detected. As an example, FLIO detects the fluorescence of macular pigment, retinal carotenoids that help protect the human fundus from light damages. Furthermore, FLIO is able to detect changes related to various retinal diseases, such as age-related macular degeneration, albinism, Alzheimer’s disease, diabetic retinopathy, macular telangiectasia type 2, retinitis pigmentosa, and Stargardt disease. Some of these changes can already be found in healthy eyes and may indicate a risk to developing such diseases. Other changes in already affected eyes seem to indicate disease progression. This review article focuses on providing detailed information on the clinical findings of FLIO. This technique detects not only structural changes at very early stages but also metabolic and disease-related alterations. Therefore, it is a very promising tool that might soon be used for early diagnostics.
机译:基于自荧光的成像技术在眼科领域变得非常重要。它们是非侵入性的,非常敏感,它们广泛用于临床惯例。常规的自荧光强度成像主要受脂血清素的强荧光的影响,荧光团可以在视网膜颜料上皮的水平上发现。然而,不同内源性视网膜荧光团可以在各种疾病中改变。荧光寿命成像眼科(FliO)是一种研究体内人底的自发荧光的成像模态。它扩展信息水平,作为调查荧光强度的补充,捕获自发荧光寿命。基于Heidelberg工程光谱的荧光寿命成像眼科镜用于研究以FOVEA为中心的30°视网膜。它检测FAF衰减在短暂[498至560nm,短频谱通道(SSC)和LONG(560至720nm,长频通道(LSC)]光谱通道,使用Bi-or Triexponential计算平均荧光寿命(τm)方法。这些是相对独立于荧光团的强度;因此,可以检测荧光较小的荧光的荧光团。作为一个例子,Flio检测黄斑色素的荧光,视网膜类胡萝卜素,有助于保护人眼睛免受光线损害。此外,FliO能够检测与各种视网膜疾病相关的变化,例如年龄相关的黄斑变性,敏锐性,阿尔茨海默病,糖尿病视网膜病变,黄斑毛细管扩诊型2型,视网膜炎菌和晕虫病。其中一些变化已经可以找到健康的眼睛,可能表明发育这种疾病的风险。已经受影响的眼睛的其他变化似乎表明疾病进展。这篇评论文章重点介绍o n提供有关Flio的临床发现的详细信息。该技术不仅检测到非常早期阶段的结构变化,还检测到代谢和疾病相关的改变。因此,它是一个非常有希望的工具,可能很快用于早期诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号